Current collaborations
PolyTherics has commercial agreements with two companies:
- Celtic Pharma for the development and commercialization of a therapeutic protein PEGylated using TheraPEG™, initially produced by PolyTherics under a research licence agreement. PolyTherics received an upfront licence fee and expects to receive clinical and regulatory milestones as well as royalties on eventual product sales. The companies are also collaborating on the PEGylation of a second therapeutic protein under a licence option agreement. See press releases.
- Nuron Biotech Inc has an exclusive option and licence agreement to use TheraPEG™ for the development of a long-acting version of their proprietary recombinant human interferon beta-1b (NU100).
PolyTherics has externally funded research agreements with the following organisations:
- DNDi (Drugs for Neglected Diseases initiative) for the development of a novel version of amphotericin B; the project is funded by DNDi.
- Zealand Pharma for the development of a PEGylated form of a novel anti-obesity drug. The project is funded jointly by the companies and supported by a Eurostars grant. See press release.
- University College London to develop a treatment for antiphospholipid syndrome ('sticky blood'). The project is supported by an Arthritis Research UK grant awarded to Professor Anisur Rahman.
- Critical Pharma for the development of better sustained release products using a combination of PolyTherics' PEGylation technology and Critical Pharma's novel drug delivery technology. The project is funded jointly by the companies and supported by a Technology Strategy Board grant. See press release.
PolyTherics also has an agreement with BioVectra, a manufacturer of specialty chemicals and biological agents, for the supply of PEG, and PEG reagents to cGMP standards. See press release.
PolyTherics also has a number of undisclosed collaborations dedicated to exploratory research on the applicability of its PEGylation technologies.